[2017 Round-up] Headache advances in 2017: a new horizon in migraine therapy

There is a great unmet need for effective and tolerable treatments for migraine. This primary headache disorder is the leading cause of neurological disability worldwide and is one of the five leading causes of long-term disability.1 The success of available antimigraine treatments is limited by inadequate effectiveness, adverse effects, and poor patient adherence. Furthermore, the drugs available for prophylaxis are not specific for migraine, but include antiepileptic drugs, β-blockers, and antidepressants.
Source: Lancet Neurology - Category: Neurology Authors: Tags: 2017 Round-up Source Type: research